Clinical significance of novel identified high-frequency tumor-specific peptides associated signature in predicting disease status of gastric cancer patients.
gastric cancer
serological test
spectrometry
tumor differentiation
tumor-specific target peptides
Journal
BioFactors (Oxford, England)
ISSN: 1872-8081
Titre abrégé: Biofactors
Pays: Netherlands
ID NLM: 8807441
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
revised:
13
07
2021
received:
02
06
2021
accepted:
22
07
2021
pubmed:
21
8
2021
medline:
25
2
2022
entrez:
20
8
2021
Statut:
ppublish
Résumé
The effectively early detection and determination of disease progression of gastric cancer (GC) are still required. An emerging demand for identifying the novel targets adherent to cancer cells has been still challenged since those valuable profilings not only could act as for early gastric tumor discovery but also being potential therapeutic views. We have retrospectively analyzed GC biopsies to identify those specific target peptides in association with disease progression. We have detected the polypeptide by liquid mass technology initiated BIO-HIGH innovational assay technology for tumor-specific target peptide identification. We have validated the accessibility and feasibility of multiple target cytotoxic T-lymphocyte for the assessment of potential molecular markers by equally comparing the frequencies of tumor peptides' loci identified in 138 GC patients. The aim was to separate peripheral blood lymphocytes by density gradient centrifugation and use specific target peptides in in vitro culture of lymphocytes. The Cell Counting Kit-8 assay was set up to prove the lymphocytes' proliferation stimulated by identified peptides. Both of GC-specific peptide and shared peptide were detected in the peripheral blood, and the frequencies and quantities were correlated with disease status and cancer differentiation, in which BHGa1510 (78%), BHGa1310 (66%), BHGa0910 (57%), BHGa0310 (54%), BHGa0210 (40%), BHGa0810 (35%), BHGa0110 (33%), and BHGa1410 (30%) were apparently scoped out as high-frequency (HF) peptides could be potentially specific tumor markers. Moreover, BHGa1410 was significantly associated with cancer progression, and BHGa0910 and BHGa0210 were significantly associated with TNM stage. The IHC data have shown that both the HF BHGa1510 and HF BHGa1310 were expressions by 100% in contrast with paracancerous tissues of 40% (p < 0.05) and 33%, respectively (p < 0.05). Those specific peptide pools could be valued in assessment of advanced tumor and differential status in GC patients.
Substances chimiques
Biomarkers, Tumor
0
Peptides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1042-1052Informations de copyright
© 2021 International Union of Biochemistry and Molecular Biology.
Références
Kumari S, Badana AK, Murali Mohan G, Shailender G, Malla R. Reactive oxygen species: a key constituent in cancer survival. Biomark Insights. 2018;13:1177271918755391.
Strilic B, Offermanns S. Intravascular survival and extravasation of tumor cells. Cancer Cell. 2017;32:282-93.
Buchheit CL, Rayavarapu RR, Schafer ZT. The regulation of cancer cell death and metabolism by extracellular matrix attachment. Semin Cell Dev Biol. 2012;23:402-11.
Aubertin K, Silva AK, Luciani N, Espinosa A, Djemat A, Charue D, et al. Massive release of extracellular vesicles from cancer cells after photodynamic treatment or chemotherapy. Sci Rep. 2016;6:35376.
Desrichard A, Snyder A, Chan TA. Cancer Neoantigens and applications for immunotherapy. Clin Cancer Res. 2016;22:807-12.
O'Donnell T, Christie EL, Ahuja A, Buros J, Aksoy BA, Bowtell DDL, et al. Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer. BMC Cancer. 2018;18:87.
Munz C. Autophagy proteins in antigen processing for presentation on MHC molecules. Immunol Rev. 2016;272:17-27.
Rossjohn J, Gras S, Miles JJ, Turner SJ, Godfrey DI, McCluskey J. T cell antigen receptor recognition of antigen-presenting molecules. Annu Rev Immunol. 2015;33:169-200.
Patel A, Kaufman HL, Disis ML. Next generation approaches for tumor vaccination. Chin Clin Oncol. 2017;6:19.
Zhang Y, Ma JA, Zhang HX, Jiang YN, Luo WH. Cancer vaccines: targeting KRAS-driven cancers. Expert Rev Vaccines. 2020;19:163-73.
No authors listed. The problem with neoantigen prediction. Nat Biotechnol. 2017;35:97.
Bassani-Sternberg M, Pletscher-Frankild S, Jensen LJ, Mann M. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol Cell Proteomics. 2015;14:658-73.
Bassani-Sternberg M, Bräunlein E, Klar R, Engleitner T, Sinitcyn P, Audehm S, et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun. 2016;7:13404.
Kalaora S, Barnea E, Merhavi-Shoham E, Qutob N, Teer JK, Shimony N, et al. Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. Oncotarget. 2016;7:5110-7.
Kiyotani K, Chan HT, Nakamura Y. Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens. Cancer Sci. 2018;109:542-9.
Miravet-Verde S, Ferrar T, Espadas-García G, Mazzolini R, Gharrab A, et al. Unraveling the hidden universe of small proteins in bacterial genomes. Mol Syst Biol. 2019;15:e8290.
Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Haglund C. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res. 2002;22:2311-6.
Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the task force of the Japanese gastric cancer association. Gastric Cancer. 2014;17:26-33.
Li W, Petruzziello F, Zhao N, Zhao H, Ye X, Zhang X, et al. Separation and identification of mouse brain tissue microproteins using top-down method with high resolution nanocapillary liquid chromatography mass spectrometry. Proteomics. 2017;17:1600419.
He C, Jia C, Zhang Y, Xu P. Enrichment-based Proteogenomics identifies microproteins, missing proteins, and novel smORFs in Saccharomyces cerevisiae. J Proteome Res. 2018;17:2335-44.
Gao YS, Wang YM, Huang JJ, et al. Expression of serum tumor markers in gastric cancer with different degrees of differentiation: significance for monitoring tumor recurrence. WCJD. 2019;27:20-5.
Park SH, Ku KB, Chung HY, Yu W. Prognostic significance of serum and tissue carcinoembryonic antigen in patients with gastric adenocarcinomas. Cancer Res Treat. 2008;40:16-21.